1 181

Cited 11 times in

Role of FGF receptors as an emerging therapeutic target in lung squamous cell carcinoma

Authors
 Sun Min Lim  ;  Hye Ryun Kim  ;  Hyo Sup Shim  ;  Ross A Soo  ;  Byoung Chul Cho 
Citation
 FUTURE ONCOLOGY, Vol.9(3) : 377-386, 2013 
Journal Title
 FUTURE ONCOLOGY 
ISSN
 1479-6694 
Issue Date
2013
MeSH
Alanine/analogs & derivatives ; Alanine/pharmacology ; Alanine/therapeutic use ; Antineoplastic Agents/pharmacology ; Antineoplastic Agents/therapeutic use ; Benzimidazoles/pharmacology ; Benzimidazoles/therapeutic use ; Carcinoma, Squamous Cell/drug therapy* ; Carcinoma, Squamous Cell/metabolism ; Gene Amplification ; Humans ; Lung Neoplasms/drug therapy* ; Lung Neoplasms/metabolism ; Molecular Targeted Therapy ; Quinazolines/pharmacology ; Quinazolines/therapeutic use ; Quinolones/pharmacology ; Quinolones/therapeutic use ; Receptors, Fibroblast Growth Factor/antagonists & inhibitors ; Receptors, Fibroblast Growth Factor/genetics ; Receptors, Fibroblast Growth Factor/metabolism* ; Signal Transduction ; Triazines/pharmacology ; Triazines/therapeutic use
Keywords
FGF receptor ; non-small-cell lung cancer ; squamous cell carcinoma ; therapeutic target
Abstract
Recent advances in molecular medicine and high-throughput sequencing technologies have achieved major cancer strategies and therapeutics over the past decades. For example, identification of oncogenic EGF receptor mutations that are present in up to 20% of lung adenocarcinoma patients confer exquisite sensitivity to EGF receptor inhibitors. However, currently known 'druggable' targets are enriched in the subgroup of adenocarcinomas and individuals who have never smoked. We present an overview of FGFs and FGF receptor (FGFR) signaling in cancer, and the role of FGFR1 as a novel druggable target in lung squamous cell carcinoma. FGFR1 amplification in lung squamous cell carcinoma is required for the survival of FGFR1-amplified cell lines. Currently, clinical reagents that target the FGFs and FGFRs are being developed accordingly. This review focuses on the emerging role of FGFR1 as a therapeutic target in lung squamous cell carcinoma and reviews current agents that are in clinical development for the treatment of FGFR-dependent cancer.
Full Text
http://www.futuremedicine.com/doi/abs/10.2217/fon.12.190?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed
DOI
10.2217/fon.12.190
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Pathology (병리학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Hye Ryun(김혜련) ORCID logo https://orcid.org/0000-0002-1842-9070
Shim, Hyo Sup(심효섭) ORCID logo https://orcid.org/0000-0002-5718-3624
Lim, Sun Min(임선민)
Cho, Byoung Chul(조병철) ORCID logo https://orcid.org/0000-0002-5562-270X
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/86501
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse